SIGMA ADVANCED SYSTEMS LIMITED has informed the Exchange regarding a press release dated March 12, 2026, titled "Press Note-Sigma Advanced Systems completes $15 million Extrovis divestment as it sharpens aerospace and defence focus."
SIGMAADV · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sigma Advanced Systems has completed the sale of its entire 36.52% stake in Switzerland-based pharmaceutical company Extrovis AG for $15 million (approximately ₹137.61 crore). The divestment is part of a portfolio rationalisation strategy that transforms Sigma into a pure-play aerospace and defence platform, freeing up capital for manufacturing expansion, strategic acquisitions, and deeper participation in global defence supply chains. The move follows Sigma's earlier acquisitions of UK-based Nasmyth Group and Delhi-based AS Strategic, which have positioned the company as a globally embedded aerospace and defence manufacturer. Additionally, the company recently secured new orders worth around ₹100 crore from India's Ministry of Defence and associated Defence PSUs.
The divestment strengthens Sigma's balance sheet with $15 million in fresh capital and signals a clear strategic shift toward aerospace and defence, which could improve investor confidence in focused growth. Shareholders may view this positively as it reduces exposure to a non-core pharma investment while funding expansion in a high-growth defence sector.